Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Visual Function for Driving in Diabetic Macular Edema and Retinal Vein Occlusion Post-Stabilization with Anti-Vascular Endothelial Growth Factor.

Clinical ophthalmology (Auckland, N.Z.)·2021

Same author

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab.

Clinical ophthalmology (Auckland, N.Z.)·2018

Same author

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab.

Clinical ophthalmology (Auckland, N.Z.)·2017

Same author

Reply: To PMID 25135548.

Journal of cataract and refractive surgery·2015

Same author

Microincisions in cataract surgery.

Journal of cataract and refractive surgery·2014

Same author

An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan(®) RC Early Analysis Review (CLEAR) trial.

Clinical ophthalmology (Auckland, N.Z.)·2014

Search research articles

Related Experiment Video

Updated: Oct 12, 2025

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Published on: May 26, 2023

Contrast Sensitivity Changes in Center Involving Diabetic Macular Edema Treated with Aflibercept.

Donald R Nixon¹, Nicholas Flinn², Claudia Enderlein³

¹Department of Surgery Northern Ontario School of Medicine Nosm, Sudbury, Ontario, P3E 2C6, Canada.

Clinical Ophthalmology (Auckland, N.Z.)

|November 19, 2021

Summary

Aflibercept treatment improved contrast sensitivity (CS) and retinal anatomy in patients with center involving diabetic macular edema (CDME). Early intervention using CS as a metric may reduce long-term deficits.

Keywords:

contrast sensitivity functional impairment residual deficit

More Related Videos

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Published on: March 11, 2016

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

Related Experiment Videos

Last Updated: Oct 12, 2025

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Published on: May 26, 2023

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Quantitative Fundus Autofluorescence for the Evaluation of Retinal Diseases

Published on: March 11, 2016

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

Area of Science:

Ophthalmology
Retinal Diseases
Pharmacology

Background:

Center involving diabetic macular edema (CDME) significantly impairs contrast sensitivity (CS).
Diabetic macular edema affects retinal anatomy and visual function.

Purpose of the Study:

To assess changes in CS and retinal anatomy in CDME patients treated with aflibercept.
To evaluate the impact of aflibercept on visual acuity and CS over 16 weeks.

Main Methods:

Prospective, open-label study of 40 CDME patients receiving five intravitreal aflibercept injections.
Measurements included central retinal thickness (CRT), best corrected visual acuity (BCVA), Pelli-Robson (PR) CS, and CamBlobs (CB) CS.

Main Results:

Aflibercept treatment reduced CRT and improved BCVA.
Significant improvements in both Pelli-Robson and CamBlobs CS were observed.
Greatest CS improvement correlated with the greatest CRT reduction.

Conclusions:

CS impairment is significant in CDME, but aflibercept treatment shows improvement.
A subset of patients may experience persistent CS deficits impacting daily life.
Earlier intervention with CS monitoring may mitigate residual visual deficits.